Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

This study has been completed.
Sponsor:
Collaborator:
Anapharm
Information provided by:
Par Pharmaceutical, Inc.
ClinicalTrials.gov Identifier:
NCT00653055
First received: April 1, 2008
Last updated: April 3, 2008
Last verified: April 2008

April 1, 2008
April 3, 2008
August 2001
December 2001   (final data collection date for primary outcome measure)
Rate and extent of absorption [ Time Frame: 240 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00653055 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions
Randomized, 4-Way Replicate Crossover, Bioequivalence Study of Cabergoline 0.5 mg Tablets and Dostinex 0.5 mg Tablets Administered as 2 x 0.5 mg Tablets in Healthy Adult Females and Males Under Fasting Conditions

To compare the rate and extent of absorption of cabergoline 0.5 mg tablets (test) versus Dostinex (reference)

To compare the rate and extent of absorption of cabergoline 0.5 mg tablets (test) versus Dostinex (reference) administered as 2 x 0.5 mg tablets under fasting conditions.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
To Determine Bioequivalence Under Fasting Conditions
  • Drug: Cabergoline
    Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
    Other Name: Dostinex
  • Drug: Dostinex
    Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
    Other Name: Cabergoline
  • Experimental: A
    Subjects received the test product, Cabergoline 0.5 mg tablets under fasting conditions
    Intervention: Drug: Cabergoline
  • Active Comparator: B
    Subjects received the reference product, Dostinex under fasting conditions
    Intervention: Drug: Dostinex
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
December 2001
December 2001   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects will be females or males, smokers or non-smokers
  • 18 years of age and older
  • Subjects should read, sign and date an Informed Consent Form prior to any study procedures
  • Subjects must complete all screening procedures within 28 days prior to the administration of the study medication

Exclusion Criteria:

  • Breast feeding female subjects
  • Clinically significant abnormalities found during medical screening
  • Any clinically significant gastrointestinal pathology or unresolved gastrointestinal symptoms susceptible of interfering with the absorption of drugs
  • Clinically significant illnesses within 4 weeks of the administration of study medication
  • Abnormal laboratory tests judged clinically significant
  • ECG abnormalities or vital sign abnormalities at screening
  • Subjects with BMI greater than or equal to 30.0
  • History of allergic reactions to cabergoline or ergot derivatives
  • Any food allergies, intolerances, restrictions, or special diet which in the opinion of the medical subinvestigator, contraindicates the subject's participation in the study
  • Positive urine drug screen at screening
  • Positive testing for hepatitis B, hepatitis C or HIV at screening
  • Positive urine pregnancy test at screening (performed on all females)
  • Use of investigational drug or participation in an investigational study, within 30 days prior to administration of the study medication
  • Donation of plasma (500 mL) within 7 days or donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication
  • History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day
  • History of drug abuse or use of illegal drugs: use of soft drugs (marijuana, pot) within 3 months of the screening visit or hard drugs (cocaine, PCP, crack)within 1 year of the screening visit
  • Subjects who have taken prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication, except for topical products without systemic absorption
  • Female subjects of childbearing potential who have had unprotected sexual intercourse with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy for at last 6 months) within 14 days prior to the study drug administration. The acceptable methods of contraception are condom + spermicide (at least 14 days prior to study drug administration), diaphragm + spermicide (at least 14 days prior to study drug administration)or intrauterine contraceptive device (placed at least 4 weeks prior to study drug administration
  • Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication
  • Subjects who have undergone clinically significant surgery within 4 weeks prior to the administration of the study medication
  • Any reason which, in the opinion of the medical subinvestigator, would prevent the subject from participating in the study
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00653055
01210
No
Alfred Elvin/Director of Biopharmaceutics, Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc.
Anapharm
Principal Investigator: Eric Masson, Pharm.D. Anapharm
Par Pharmaceutical, Inc.
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP